Allogenica

📍 Villeurbanne, France🗓 Founded 2022👥 9 employees💰 Last funded Jan 2022
Biotechnology Research
LinkedIn
Allogenica is a Lyon-based biotechnology company specialized in the development of an emerging class of cancer therapy, called CAR-T cells (Chimeric Antigen Receptor T-cells). Allogenica has developed a bioproduction platform that relies on the manipulation of hematopoietic stem cells and their derivatives with the aim of developing allogenic "off-the-shelf" CAR-T cells. Allogenica will offer the next-generation cancer treatment ready to use, at low cost and safer than current treatments, in order to treat all patients who need it. The start-up is based in Cancer Research Center of Lyon/Centre Léon Bérard.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Allogenica?
Allogenica has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Allogenica last raise funding?
The most recent investment in Allogenica recorded on gritt.io was in January 2022.
When was Allogenica founded?
Allogenica was founded in 2022.
What industry is Allogenica in?
Allogenica operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Allogenica based?
Allogenica is headquartered in Villeurbanne, France.